It’s now prohibited in France to buy or possess kratom, a psychotropic plant native to Southeast Asia, “taking into account the serious health risks” linked to its consumption, announced the Medicines Agency ( ANSM).
In previous reports, exactly the same agency had highlighted a genuine amount of 20 cases of alleged toxicity associated with Kratom in France. Because it happens in studies by US agencies, generally the topics were on other drugs like heroin or codeine.
Investigations have shown that the consumption of kratom can be “causing dependence, withdrawal syndrome, anorexia, weight loss, psychotic decompensation and toxic hepatitis”, details the drug gendarme.
In their newest announcement on their web page and social networking, the French agency supplies a poor description justifying their decision. A maneuver that seems supported by fake information headlines of scientific evidence rather.
Article R5132-88 of the French Public Health code bans possession, manufacturing, exports, imports, offer and use of any substances included in the psychotropic substances list, in which Kratom is now included.
The ANSM alludes to the FDA and its particular recommendations about Kratom to spell out their decision. On the other hand, the FDA reviews don’t provide clean scientific facts that justify banning Kratom either.
The psychoactive effects of this plant, whose scientific name is Mitragyna speciosa, “are due to the many alkaloids it contains, in particular mitragynine and 7-hydroxymitragynine, active on the opioid receptors (morphine receptors)” present in the organization.
In the United States, where kratom is legal in 43 states, health authorities recorded nearly 100 deaths in consumption between April 2016 and December 2017. The FDA health agency published a warning regarding imports in 2012, meaning that deliveries on arrival in the United States can be seized and a health warning was issued in 2017.